Zenas BioPharma’s (ZBIO) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Zenas BioPharma (NASDAQ:ZBIO) in a report issued on Tuesday,Benzinga reports. HC Wainwright currently has a $44.00 price target on the stock.

ZBIO has been the topic of several other research reports. Evercore began coverage on Zenas BioPharma in a report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 price objective on the stock. Wall Street Zen downgraded Zenas BioPharma from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Monday, December 29th. Jefferies Financial Group restated a “buy” rating and issued a $48.00 price target on shares of Zenas BioPharma in a report on Tuesday, January 6th. Finally, Wedbush reiterated an “outperform” rating and set a $45.00 price objective on shares of Zenas BioPharma in a report on Monday, December 22nd. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $43.14.

Zenas BioPharma Stock Performance

NASDAQ:ZBIO opened at $21.48 on Tuesday. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66. The firm has a market cap of $1.15 billion, a PE ratio of -3.04 and a beta of -1.50. The firm has a 50 day simple moving average of $28.32 and a 200-day simple moving average of $25.52. Zenas BioPharma has a 1-year low of $6.11 and a 1-year high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last announced its earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Insider Activity at Zenas BioPharma

In other news, CEO Leon O. Moulder, Jr. acquired 57,000 shares of Zenas BioPharma stock in a transaction dated Monday, February 2nd. The shares were acquired at an average cost of $17.96 per share, with a total value of $1,023,720.00. Following the purchase, the chief executive officer directly owned 423,155 shares of the company’s stock, valued at approximately $7,599,863.80. This trade represents a 15.57% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders bought 157,000 shares of company stock valued at $2,662,720. Company insiders own 16.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Quarry LP lifted its position in Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after buying an additional 291 shares in the last quarter. CWM LLC raised its stake in shares of Zenas BioPharma by 48.3% in the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after acquiring an additional 709 shares during the period. Two Sigma Investments LP lifted its holdings in shares of Zenas BioPharma by 3.9% during the 3rd quarter. Two Sigma Investments LP now owns 20,382 shares of the company’s stock valued at $452,000 after acquiring an additional 765 shares in the last quarter. Bank of America Corp DE boosted its position in Zenas BioPharma by 5.8% during the 3rd quarter. Bank of America Corp DE now owns 14,809 shares of the company’s stock worth $329,000 after purchasing an additional 818 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new stake in Zenas BioPharma during the 4th quarter worth $38,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.